Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Risk Communication Strategy May Include Overhaul Of Labeling Language

Executive Summary

As FDA assesses its new risk management powers and overall drug safety strategy, it continues to focus on how to revise what has been its primary communications tool for decades - product labeling

You may also be interested in...

Supreme Court Ruling In Wyeth v. Levine: What’s The Liability For FDA?

How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies. But how might the decision affect FDA, and by extension, the drug review process

FDA To Evaluate Prescribing In Pregnancy With “Mental Modeling” Of Doctors

An FDA study to monitor prescribing decisions among care physicians who treat pregnant women could help pave the way for a better understanding of how to communicate drug risks in general

FDA Risk Communication Research May Follow Critical Path To Avoid OMB

FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts